Zynlonta (loncastuximab tesirine-lpyl)

P2, N=21, Active, not recruiting, Shayna Sarosiek, MD | Recruiting --> Active, not recruiting | N=36 --> 21

To address this, we present a new cell/protein "Double Insurance" targeting strategy through constructing a novel antibody-TCI conjugate (Ab-TCI), which comprises a monoclonal antibody (Loncastuximab), a TCI (As-Ibt) for Bruton's tyrosine kinase (BTK), and between them an arsenic-thiol bond as a new cleavable linker...To our knowledge, this is the first Ab-TCI enabling simultaneous dual targeting capabilities for cancer cells and kinase, achieving a remarkable improvement in drug efficacy. New potent dual-targeting Ab-TCIs could be inspired by integrating different FDA approved TCIs and antibodies through our strategy for cancer treatment.

P2, N=20, Recruiting, University of Washington | N=40 --> 20 | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Dec 2026 --> Dec 2027

P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027

P1/2, N=23, Not yet recruiting, University of Utah

P2, N=49, Recruiting, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Recruiting

P2, N=50, Recruiting, Istituto Clinico Humanitas | Active, not recruiting --> Recruiting

P2, N=49, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting

P3, N=440, Active, not recruiting, ADC Therapeutics S.A. | N=228 --> 440

P2, N=50, Active, not recruiting, Istituto Clinico Humanitas | Recruiting --> Active, not recruiting

Conventional platinum-based or gemcitabine- and bendamustine-containing regimens retain a role for short-term disease control but offer limited durability. In contrast, novel antibody-based therapies, including polatuzumab-containing combinations, loncastuximab tesirine, and tafasitamab plus lenalidomide, have expanded treatment options with improved tolerability. Most notably, CD20 × CD3 bispecific antibodies represent a major therapeutic advance, providing off-the-shelf immune engagement with predominantly outpatient administration. From a practical perspective, early identification of reversible barriers to CAR T-cell therapy and timely use of bispecific antibodies or other antibody-based regimens are critical to achieve rapid disease control, preserve organ function, and, when feasible, restore eligibility for cellular therapy.

P1/2, N=104, Recruiting, Universitaet Muenster